Abstract 281P
Background
Based on Globocan 2020, prostate cancer is the second most common male cancer worldwide. One of the main treatments for localized prostate cancer patients is definitive radiotherapy. Regarding limited access to intensity modulated radiation therapy and other modern techniques in developing countries, most patients in these countries are still being treated with 3D conformal RT techniques. Considering the fact that there is association between local control and prostate cancer specific mortality, we aimed to investigate the local control in unfavorable intermediate and high risk prostate cancer patients whom underwent definitive radiotherapy with 3D conformal technique.
Methods
50 patients involved in this study. They all were treated by definitive radiotherapy with 3D conformal technique since 2014 in the Radiation Department of Hamadan University of Medical Sciences. The required data was collected through the assessment of patient's' medical records. All patients were treated using a 4-field (Box) 3D technique with a total dose of 70 Gy. Additionally, in all patients, the whole pelvis was covered in the initial phase of treatment (46Gy).
Results
After the median follow up of 45 month 13 treatment failure was seen in the study population. Bio-chemical relapse occurred in 13 patients (26%). Seven patients were found to have local recurrences (14%). Distant failure, all in bone, occurred in 6 patients (12%). The 3year BCR free survival, local failure free survival and metastases free survival were 76%, 88%, and 88% respectively. The most important factor for BCR, distant failure, and overall failure was extension of disease (T stage).
Conclusions
Our results were lower compared to the results announced in the developed countries' center. This indicates that the use of modern radiotherapy techniques has been essential in prostate cancer treatment, both due to the increased treatment effectiveness and the reduction of treatment side effects. It is vital for developing countries to plan their health care policies in a way that improves patients' access to these innovative techniques. And governments should allocate a budget for updating radiotherapy devices in their country's infrastructure planning.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
R. Bayani.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
561P - Mechanisms of osimertinib resistance using circulating tumor DNA analyses for EGFR-mutated non-small cell lung cancer, results from ELUCIDATOR: A prospective observational multicenter study
Presenter: Daijiro Harada
Session: Poster Display
Resources:
Abstract
562P - First-line (1L) osimertinib (osi) ± platinum-pemetrexed in patients (pts) with EGFRm advanced NSCLC: FLAURA2 China cohort
Presenter: Yan Yu
Session: Poster Display
Resources:
Abstract
563P - Real-world effectiveness and safety of first-line osimertinib for EGFR-mutated advanced NSCLC in China (FLOURISH study)
Presenter: Jianya Zhou
Session: Poster Display
Resources:
Abstract
564P - Co-occurring EGFR p.E709X mutation affects the treatment response to the third-generation EGFR-TKIs in EGFR p.G719X-mutant patients with advanced NSCLC
Presenter: Wen Feng Fang
Session: Poster Display
Resources:
Abstract
565P - Genome-guided targeted therapy combination improves survival in patients with advanced EGFR mutation positive NSCLC failing osimertinib
Presenter: Molly Li
Session: Poster Display
Resources:
Abstract
566P - Safety of tepotinib + osimertinib in EGFR-mutant NSCLC with MET amplification after first-line osimertinib
Presenter: Chong Kin Liam
Session: Poster Display
Resources:
Abstract
567P - Furmonertinib in combination with bevacizumab and intrathecal chemotherapy as later-line re-challenge treatment in EGFR –mutated NSCLC patients with leptomeningeal metastasis after third-generation EGFR-TKIs treatment failure
Presenter: Fang Cun
Session: Poster Display
Resources:
Abstract
568P - First-line (1L) osimertinib + platinum-pemetrexed in EGFR-mutated (EGFRm) advanced NSCLC: Updated FLAURA2 safety run-in (SRI) results
Presenter: David Planchard
Session: Poster Display
Resources:
Abstract
569P - Whole-transcriptome sequencing of transformed small-cell lung cancer from EGFR-mutated lung adenocarcinoma reveals LUAD–like and SCLC–like subsets
Presenter: Chan-Yuan Zhang
Session: Poster Display
Resources:
Abstract
570P - First-line osimertinib for patients with advanced NSCLC harboring EGFR mutations: A real-world study
Presenter: Wenxiang Ji
Session: Poster Display
Resources:
Abstract